纯度 | >85%SDS-PAGE. |
种属 | Human |
靶点 | PRKACB |
Uniprot No | P22694 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 2-351aa |
氨基酸序列 | GNAATAKKG SEVESVKEFL AKAKEDFLKK WENPTQNNAG LEDFERKKTL GTGSFGRVML VKHKATEQYY AMKILDKQKV VKLKQIEHTL NEKRILQAVN FPFLVRLEYA FKDNSNLYMV MEYVPGGEMF SHLRRIGRFS EPHARFYAAQ IVLTFEYLHS LDLIYRDLKP ENLLIDHQGY IQVTDFGFAK RVKGRTWTLC GTPEYLAPEI ILSKGYNKAV DWWALGVLIY EMAAGYPPFF ADQPIQIYEK IVSGKVRFPS HFSSDLKDLL RNLLQVDLTK RFGNLKNGVS DIKTHKWFAT TDWIAIYQRK VEAPFIPKFR GSGDTSNFDD YEEEDIRVSI TEKCAKEFGE F |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRKACB重组蛋白的3篇示例参考文献(注:文献信息为虚构示例,实际文献需通过学术数据库检索获取):
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant PRKACB in Escherichia coli"
**作者**: Zhang Y, et al.
**摘要**: 本研究通过在大肠杆菌中成功表达并纯化PRKACB重组蛋白,验证了其cAMP依赖性激酶活性,并利用体外磷酸化实验揭示了其对下游靶蛋白的调控机制。
2. **文献名称**: "Structural Insights into PRKACB Activation by cAMP Using Recombinant Protein Crystallography"
**作者**: Smith JL, et al.
**摘要**: 通过重组PRKACB蛋白的晶体结构解析,阐明了cAMP结合诱导的构象变化如何激活激酶活性,为设计靶向该蛋白的药物提供了结构基础。
3. **文献名称**: "PRKACB Recombinant Protein Modulates Neuronal Signal Transduction in vitro"
**作者**: Chen H, et al.
**摘要**: 利用HEK293细胞表达的重组PRKACB蛋白,证实其在神经元突触可塑性中的关键作用,并发现其异常活性与神经系统疾病的相关性。
---
**建议**:实际文献可通过PubMed、Google Scholar等平台,以关键词“PRKACB recombinant protein”“PRKACB expression”“kinase activity”等检索,重点关注蛋白功能、结构或疾病机制研究。
PRKACB (Protein Kinase cAMP-Activated Catalytic Subunit Beta) is a crucial enzyme in the cAMP-dependent protein kinase (PKA) signaling pathway, which regulates diverse cellular processes, including metabolism, gene expression, and cell proliferation. As one of the catalytic subunits of PKA, PRKACB works in conjunction with regulatory subunits to mediate cAMP signaling. Upon cAMP binding, the regulatory subunits release the catalytic subunits (PRKACA or PRKACB), allowing them to phosphorylate downstream targets. PRKACB shares structural homology with PRKACA (the alpha isoform) but exhibits distinct tissue expression patterns, with higher abundance in brain tissues, suggesting specialized roles in neuronal function and development.
Recombinant PRKACB protein is engineered using expression systems like *E. coli* or mammalian cells to produce a purified, functional form of the enzyme for research. This recombinant protein retains kinase activity, enabling studies on PKA signaling mechanisms, substrate specificity, and interactions with regulatory subunits or inhibitors. Its applications span drug discovery, structural biology, and disease modeling, particularly in neurological disorders, cancers, and metabolic diseases linked to PKA dysregulation. For example, PRKACB mutations or altered expression have been implicated in tumors, neurodevelopmental disorders, and circadian rhythm abnormalities. Researchers also use recombinant PRKACB to screen small-molecule modulators or investigate isoform-specific functions, addressing gaps in understanding how PKA isoforms differentially regulate cellular responses. The availability of recombinant PRKACB accelerates mechanistic studies and therapeutic targeting of cAMP-PKA pathways in precision medicine.
×